/ PFE
/ Earnings
Pfizer Tops EPS Expectations in Q3 2025 Despite Revenue Decline
Pfizer reported Q3 2025 revenue of $16.7 billion and adjusted EPS of $0.87, beating expectations and prompting a full-year EPS guidance raise.
November 04, 2025
From Defense to Pharma to Energy: Dividend Opportunities Across Sectors
Lockheed’s defense backlog, Pfizer’s biotech expansion, and Schlumberger’s energy contracts make for safe and potentially lucrative dividend plays heading into year-end.
October 06, 2025
Pfizer Shares Gain Amid Reports of Deal with the US Government
Pfizer stock climbed over 3% on news of an impending drug-pricing deal with the Trump administration.
September 30, 2025
Pfizer (PFE) Beats Expectations in Q2 2025, Raises EPS Guidance
Pfizer's second-quarter 2025 results exceeded expectations with a 10% revenue growth and an adjusted EPS of $0.78.
August 05, 2025
Pfizer Reports Q1 2025: Revenue Down 8% y/y
Pfizer's Q1 2025 results indicate a sound earnings performance, with adjusted EPS surpassing expectations.
April 29, 2025More from The Tokenist / PFE
Pfizer (NYSE: PFE) Reports Better than Expected Q4 Results
February 04, 2025
Pfizer Targets Up to $64B Revenue in 2025 Amid Strategic Cost Savings
December 17, 2024
Back to 
